<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00657241</url>
  </required_header>
  <id_info>
    <org_study_id>111704</org_study_id>
    <nct_id>NCT00657241</nct_id>
  </id_info>
  <brief_title>Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril</brief_title>
  <official_title>Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      14-week single blind, double baseline, forced-titration, cross-over comparison of the cardiac&#xD;
      benefits of Coreg CR compared to valsartan added to existing ACE inhibition&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combination drug therapy is necessary for optimal blood pressure reduction and current&#xD;
      guidelines mandate the concomitant use of ACE inhibitors and β-blockers in most patients at&#xD;
      significant risk for cardiovascular disease (CVD) events. There is also continuing interest&#xD;
      in combining angiotensin receptor blockers (ARBs) with ACE inhibitors in hypertension based&#xD;
      on the unsubstantiated belief that &quot;more complete&quot; renin-angiotensin system inhibition is&#xD;
      desirable. It is more attractive physiologically to combine a long-acting β-blocker with&#xD;
      vasodilatory actions (Coreg CR) with an ACE inhibitor because this combination addresses more&#xD;
      directly the two fundamental hemodynamic changes needed to reduce CVD events: lowering&#xD;
      systolic BP (afterload) and lowering heart rate; the product of the two is a reliable&#xD;
      surrogate for reduced cardiac work. In fact, clinical trial data suggest that there is no&#xD;
      appreciable additional BP lowering when ARBs are added to ACE inhibitors and neither class&#xD;
      lowers heart rate. The present proposal is designed to demonstrate the superior&#xD;
      &quot;cardioprotection&quot; of Coreg CR compared to ARB (valsartan) when each is added to background&#xD;
      ACE inhibitor therapy. Principal dependent variables include ambulatory cardiac work (24-hour&#xD;
      mean ambulatory systolic BP x heart rate) and laboratory stress responses (central systolic&#xD;
      time-tension indices derived from arterial tonometry pre- and post-bicycle exercise).&#xD;
      Secondary hemodynamic variables will define changes in flow and pressure (e.g. central&#xD;
      systolic BP and forward and reflected pressure wave estimations).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in resting CTTI (cardiac work) between Coreg and valsartan.</measure>
    <time_frame>3 weeks, 6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valsartan 160 mg (one week); valsartan 320 mg (3 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coreg CR 20 mg (one week) and Coreg CR 40 mg (3 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carvedilol</intervention_name>
    <description>Coreg CR 20 mg (one week) and Coreg CR 40 mg (3 weeks).</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Coreg CR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan</intervention_name>
    <description>Valsartan 160 mg (one week); valsartan 320 mg (3 weeks)</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with residual (uncontrolled) hypertension on lisinopril monotherapy, defined&#xD;
             as 24-hour ambulatory diastolic BP &gt;85 mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A subject meeting any of the following conditions will be excluded from the study:&#xD;
&#xD;
          -  History of serious adverse effects with ACE inhibitor, Coreg, or valsartan&#xD;
&#xD;
          -  Known or suspected causes of secondary hypertension (e.g., renovascular stenosis,&#xD;
             primary hyperaldosteronism)&#xD;
&#xD;
          -  Known ischemic heart disease requiring beta-blocker therapy (includes angina, prior&#xD;
             transmural myocardial infarction, coronary artery bypass graft surgery or percutaneous&#xD;
             transluminal coronary angioplasty or stenting within 6 months prior to study entry).&#xD;
&#xD;
          -  Heart failure (NYHA Functional Class II-IV)&#xD;
&#xD;
          -  Obstructive valvular heart disease or obstructive hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Presence of clinically significant ventricular or supraventricular arrhythmias (e.g.&#xD;
             atrial fibrillation/flutter), pre-excitation syndrome, second or third degree AV&#xD;
             block, other conduction defects necessitating the implantation of a permanent cardiac&#xD;
             pacemaker, or sick sinus syndrome.&#xD;
&#xD;
          -  Chronic kidney disease (serum creatinine &gt;2.5 within past 6 months)&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus (i.e., a fasting blood glucose &gt;200 mg/dL [&gt;11.1&#xD;
             mmol/L] or hemoglobin A1c &gt; 10%&#xD;
&#xD;
          -  History of alcohol or other drug abuse within 6 months prior to enrollment&#xD;
&#xD;
          -  Concomitant treatment or probable need for treatment with prohibited medications.&#xD;
             NSAIDs, diabetes medications and other chronic meds are permitted if continued&#xD;
             throughout study without dosage change.&#xD;
&#xD;
          -  Any other medical condition which renders the subject unable to complete the study or&#xD;
             which would interfere with optimal participation in the study or produce a significant&#xD;
             risk to the subject&#xD;
&#xD;
          -  Those with persistent systolic BP elevations above 179 mmHg will be discontinued from&#xD;
             the study as will those with any significant adverse effect of medication.&#xD;
&#xD;
          -  Positive pregnancy test or failure to practice adequate contraception in women of&#xD;
             child-bearing potential&#xD;
&#xD;
          -  Bronchospastic asthma requiring chronic steroid or inhaler therapy&#xD;
&#xD;
          -  Any women with child-bearing potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph L Izzo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUNY Buffalo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erie County Medical Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>April 9, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <last_update_submitted>June 30, 2010</last_update_submitted>
  <last_update_submitted_qc>June 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Joseph L. Izzo, Jr., M.D.</name_title>
    <organization>SUNY Buffalo</organization>
  </responsible_party>
  <keyword>cardiac work</keyword>
  <keyword>coreg cr</keyword>
  <keyword>valsartan</keyword>
  <keyword>tonometry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

